PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2005/53 - MEDA/VIATRIS/DAGRA
Acquiring
Meda AB
Description
a specialized Swedish undertaking in the pharmaceutical industry; it carries out its activity in three therapeutic areas: pain and inflammation, cardiovascular diseases and diabetes, and gastrointestinal diseases;
Acquired
Viatris Holding GmbH
Description
a German pharmaceutical company that centres its activity on developing, producing and marketing original and licensed pharmaceutical products in the following therapeutic areas: respiratory disorders and allergies, pain and neurology, dermatology and hygiene, and metabolism regulation.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Case description
On 22 August 2005 notification was submitted of the present merger, consisting of the acquisition by the pharmaceutical company MEDA AB, hereinafter referred to as "MEDA", from VIATRIS HOLDING (Luxemburg) SARL, of the undertaking VIATRIS Holding GmbH, hereinafter referred to as "VIATRIS", which, in Portugal, holds the total registered capital of the undertaking Viatris Farmacêutica SA, which in turn holds the total registered capital of DAGRA - Produtos Farmacêuticos SA.
Timeline
2005-09-26
Competition Authority approves acquisition of the undertaking VIATRIS Holding GmbH by MEDA AB.
Click here to see your activities